
Chemicals used in cosmetics and household goods linked to 350,000 deaths every year, warn experts
Called phthalates, the chemicals are often added to plastic items like food containers, as well as makeup, shampoo, nail varnish, hair spray and perfume.
1
They also crop up in detergents, solvents, plastic toys and bug repellents.
These chemicals break down into microscopic particles and are ingested, with studies suggesting that frequent exposure to them could cause health problems.
Research has previously linked phthalate exposure to an increased risk of such as obesity, diabetes, fertility issues and even cancer.
Now, researchers from NYU Langone Health say hundreds of thousands of global deaths from heart disease could be linked to phthalates.
They suggested that 356,000 people may have died from phthalate-related heart disease in 2018 alone.
Their study focused on a kind of phthalate called di-2-ethylhexyl phthalate (DEHP), which is used to make food containers, medical equipment, and other plastic items softer and more flexible.
"The past decade has presented a new and previously unrecognised risk for cardiovascular disease: exposure to plastic polymers and their chemical additives," they wrote in the journal eBiomedicine.
"Of particular concern are phthalates, particularly one class of DEHP, which are used to soften polyvinylchloride (PVC) plastics."
Previous research has suggested that frequent DEHP exposure may trigger an overactive immune response or inflammation in the heart's arteries, which over time is associated with increased risk of heart attack or stroke.
They examined the impact of DEHP on global deaths across 200 countries and territories, using health and environmental data, as well as urine samples containing chemical breakdown products left by the plastic additive.
The 6 everyday items 'poisoning' you with toxic plastics linked to cancer
The authors estimated that DEHP exposure contributed to 356,238 deaths in 2018 among men and women aged 55 to 64.
They said this accounted for more than 13 percent of all global deaths from heart disease.
Lead author Sara Hyman, an associate research scientist at NYU Grossman School of Medicine, said: 'By highlighting the connection between phthalates and a leading cause of death across the world, our findings add to the vast body of evidence that these chemicals present a tremendous danger to human health."
While phthalates are widely used across the world, they found people in the Middle East, South Asia, East Asia, and the Pacific were more vulnerable to health effects.
Three fourths of the 356,238 deaths occurred in these regions.
"Our study provides, to the best of our knowledge, a previously unknown global estimation of the burden of cardiovascular mortality attributable to DEHP exposure," researchers said.
"The present disease burden model not only quantifies DEHP-related cardiovascular deaths but also highlights significant geographic disparities, showing that regions such as Africa, the Middle East, and South Asia bear the highest burden of DEHP-attributable deaths.
"By focusing on plastic production, consumption, and disposal our findings demonstrate the wide-reaching public health implications of DEHP exposure and how plastic-related chemicals disproportionately impact countries on the Asian continent."
What you need to know about phthalates
Phthalates are chemical compounds mainly used as plasticisers - additives that make plastic flexible.
There has been increased focus on phthalates due to their widespread use in our everyday products, and because there are more and more studies that suggest that phthalates may cause long-term adverse health effects.
Here are some of the product categories that may contain phthalates:
Plastic toys
Coatings
Cosmetics and personal care
Wood finishes
Detergents
Adhesives
Plastic FCMs and other plastic materials
Lubricants
Solvents
Insecticides
Building materials
India had the highest death count, at 103,587 deaths, followed by China and Indonesia.
Researchers said a possible explanation for this could be that these countries face higher rates of exposure to the chemicals, possibly because they are undergoing a boom in plastic production but with fewer manufacturing restrictions than other regions.
Senior author Dr Leonardo Trasande said: 'There is a clear disparity in which parts of the world bear the brunt of heightened heart risks from phthalates.
"Our results underscore the urgent need for global regulations to reduce exposure to these toxins, especially in areas most affected by rapid industrialisation and plastic consumption."
Dr Trasande noted that the study doesn't show that that DEHP is the lone or direct cause of heart disease, nor did researchers take into account the possible health risks of other types of phthalates.
The researchers also didn't examine other age groups except 55 to 64-year-olds.
As a result, the overall death toll from heart disease connected to these chemicals is likely much higher, Dr Trasande claimed.
Researchers next plan to track how reductions in phthalate exposure may, over time, affect global mortality rates, as well as to expand the study to other health concerns posed by the chemicals, such as premature birth.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


ITV News
08-08-2025
- ITV News
Patients to be fast-tracked on to new head and neck cancer vaccine trial
People with head and neck cancer in England will be fast-tracked on to a clinical trial for a 'potentially transformative' vaccine under new NHS plans. The first patients have received the jab, which uses mRNA technology to train the immune system to fight cancer, with more set to be enrolled at their nearest NHS hospital. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. Aggressive forms are difficult to treat, with high rates of recurrence and two-year survival rates under 50%. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of human papillomavirus (HPV). These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. More than 100 patients with advanced forms of the disease will be matched to the trial, known as AHEAD-MERIT (BNT113), which will run at 15 hospitals over the next year. Health minister Karin Smyth described the plan as a 'massive win for cancer patients'. She added: 'These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. 'By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer.' NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: 'It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay.' Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial 'offers crucial hope to those living with advanced stages of cancer'. 'While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones,' she added. Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: 'As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. 'With this aggressive cancer you live in the fear of reoccurrence every day – so anything that could help control the disease or give people peace of mind is groundbreaking – it'll allow people to get on with their lives and move forward.' The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: 'The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. 'Research into personalised cancer treatments is vital. 'There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. 'That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer.'

South Wales Argus
08-08-2025
- South Wales Argus
Patients to be fast-tracked on to new head and neck cancer vaccine trial
The first patients have received the jab, which uses mRNA technology to train the immune system to fight cancer, with more set to be enrolled at their nearest NHS hospital. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. Aggressive forms are difficult to treat, with high rates of recurrence and two-year survival rates under 50%. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of human papillomavirus (HPV). These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. More than 100 patients with advanced forms of the disease will be matched to the trial, known as AHEAD-MERIT (BNT113), which will run at 15 hospitals over the next year. Health minister Karin Smyth described the plan as a 'massive win for cancer patients'. She added: 'These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. 'By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer.' NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: 'It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay.' Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial 'offers crucial hope to those living with advanced stages of cancer'. 'While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones,' she added. Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: 'As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. 'With this aggressive cancer you live in the fear of reoccurrence every day – so anything that could help control the disease or give people peace of mind is groundbreaking – it'll allow people to get on with their lives and move forward.' The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: 'The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. 'Research into personalised cancer treatments is vital. 'There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. 'That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer.'

Leader Live
08-08-2025
- Leader Live
Patients to be fast-tracked on to new head and neck cancer vaccine trial
The first patients have received the jab, which uses mRNA technology to train the immune system to fight cancer, with more set to be enrolled at their nearest NHS hospital. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. Aggressive forms are difficult to treat, with high rates of recurrence and two-year survival rates under 50%. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of human papillomavirus (HPV). These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. More than 100 patients with advanced forms of the disease will be matched to the trial, known as AHEAD-MERIT (BNT113), which will run at 15 hospitals over the next year. Health minister Karin Smyth described the plan as a 'massive win for cancer patients'. She added: 'These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. 'By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer.' NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: 'It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay.' Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial 'offers crucial hope to those living with advanced stages of cancer'. 'While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones,' she added. Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: 'As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. 'With this aggressive cancer you live in the fear of reoccurrence every day – so anything that could help control the disease or give people peace of mind is groundbreaking – it'll allow people to get on with their lives and move forward.' The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: 'The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. 'Research into personalised cancer treatments is vital. 'There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. 'That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer.'